Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Retrophin (RTRX) Starts Presentation at the Biotech Showcase 2013 Conference

Retrophin is a biotech company focused on discovering and developing treatments for rare and life-threatening diseases. RTRX is currently developing treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases. The company’s lead compound, RE-021, formerly known as DARA, is scheduled to begin enrollment in a potentially pivotal phase 2 clinical trial for FSGS in 1H13. For further information, visit the company’s Web site at www.retrophin.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below:

This entry was posted in EBD Group Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *